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Summary As yet, there is no reported study of chromosome allele loss in fibrolamellar carcinoma (FLC), a
distinct, rare variant of hepatocellular carcinoma (HCC). We searched for evidence of allele loss in FLC using
18 DNA probes for 10 chromosomes and compared the pattern of loss with our series of HCC. Two of the
probes, AMS32 (lq42-43) and cMS621 (5p) showed allele losses in one tumour, while other probes showed no
loss. The frequency of allele loss in FLC was much lower than in HCC, which may be associated with their
different prognoses.
Fibrolamellar carcinoma (FLC) is a rare variant of hepato-
cellular carcinoma (HCC). It occurs in younger patients
(20-30 years) with an equal sex incidence. Cirrhosis and
hepatitis B virus (HBV) infections are rarely seen in patients
with FLC and it is thought that the tumour may arise from
areas of focal nodular hyperplasia (Vecchio et al., 1984). The
prognosis of patients with FLC is better than that of HCC
with an average survival of44 months compared to 6 months
in HCC (Craig et al., 1980). It is these differences in clinico-
pathological features which would suggest that FLC and
HCC have a different pathogenesis.
Genes which are involved in tumorigenesis appear to
belong to two classes, the cellular oncogenes and tumour
suppressor genes. Normally, cell proliferation is controlled by
a balance between growth-promoting proto-oncogenes and
growth-limiting tumour suppressor genes. Malignant activa-
tion of the former occurs by point mutation, transposition or
amplification, whereas loss of function in the latter group can
be caused by complete gene deletion as well as by intra-
genic mechanisms (Aaronson, 1991; Weinberg, 1991). Where
constitutional tissue is heterozygous at a particular
gene locus, consistent reduction to homozygosity in tumori-
genesis, caused by loss of genetic material, is taken as
evidence for the presence of a tumour suppressor gene at or
near that site. Chromosome allele loss, or loss of heterozy-
gosity, occurs in all types of solid tumours analysed (Lasko
et al., 1991), and the frequency may be positively correlated
with clinical prognosis, for example in colorectal cancer
(Vogelstein et al., 1989).
Recently, we and others have studied the pattern of
chromosome allele loss (loss of genetic material) in HCC
(Ding et al., 1991; Zhang et al., 1990; Fujimori et al., 1991).
In FLC, no such studies have been reported. Here we report
the first study of chromosome allele loss in FLC with 18
DNA restriction fragment length polymorphism (RFLP)
probes and compare the pattern of allele loss with that of
HCC.
that both of these hospitals are national referral centres for
liver cancers. Patients' clinical data are presented in Table I.
None of the patients received chemotherapy or radiotherapy
before surgery. Surgical biopsies from tumoral and non-
tumoral liver tissues were snap frozen in liquid nitrogen at
the time of operation. Lymphocytes from peripheral blood
obtained pre-operatively were also used as a source of normal
DNA. Tissue was stored at - 70°C until DNA extraction. A
portion of each tumour sample was examined histologically
to confirm the type of tumour present.
DNA extraction andanalysis
DNA was prepared from blood and tissue samples by stan-
dard phenol/chloroform methods (Sambrook et al., 1989).
Southern analyses were done as previously described (Ding et
al., 1991). The 18 RFLP probes for chromosomes 1, 5, 7, 9,
11, 12, 13, 16, 17 and 18 and the appropriate restriction
enzymes are listed in Table II. These 18 probes were those
used in the previous study on HCC (Ding et al., 1991),
including probes screening regions near or flanking loci of
most known tumour suppressor genes (Table II). If two
alleles appeared as two separate bands in the resultant auto-
radiograph of the constitutional DNA, the patient was con-
sidered 'informative', or heterozygous, for the particular
marker. Complete deletion or great loss of intensity of one
band in the tumour DNA indicated an allele loss.
Statistical analysis
The significance of the difference in the frequency of allele
loss was tested by a standard method for comparison of
proportions (Bland, 1987).
Results
Table II shows the overall pattern of allele loss in fibrola-
mellar carcinoma. Overall, 55/78 Southern blots were infor-
Materials and methods
Patients and biopsies
Due to the rarity of the condition, in the past 3 years we
were able to study only five patients with fibrolamellar car-
cinoma who underwent surgical resection of their tumours at
Hammersmith or the Royal Free Hospitals, despite the fact
Table I Clinical data offive patients with fibrolamellar carcinomaa
Case HBV Liver FLC No. ofallele
no. Sex Age status" cirrhosis recurrence loss in FLC
I F 23 - - - 0
2 M 55 - - - 0
3 M 23 - - + 2
4c M 60 - - _ 0
5 F 19 - - - 0
a_: negative or absent; +: positive or present. bHBV status was
determined by blood assay and Southern analysis of hepatic tissue
DNA, using the HBV genome probe pEco63. 'This patient had a
synchronous HCC. Two tumours were resected together.
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Table II Chromosome allele loss in fibrolamellar carcinoma
Allele
Probe Chromosomal region Enzyme used losSa
kMS1b lp33-35 Hinfl 0/3
AMS32 Iq42-43 AluI 1/3
cMS621 5p Hinfl 1/4
ECB27C 5q21 BglII 0/0
YN5.48c 5q22 MspI 0/3
AMS8 5q35-qter Hinfl 0/2
AMS31 7pter-q22 Hinfl 0/4
pAg3 7p3l.3-qter Hinfl 0/3
EFD126.3 9q34 PvuII 0/2
H-ras llpl5 BamHl 0/3
pMS51 11ql3 HaeIII 0/4
AMS43 12q24.3-qter Hinfl 0/5
cMS626d 13q AluI 0/4
3'HVR 16p13.3 PvuII 0/4
pulB1148 16q22.1 TaqI 0/1
p144-D6e 17pl3 RsaI 0/2
pYNZ.223 17pl3 RsaI 0/5
cMS440 18q HaeIII 0/3
aNo. withalleleloss/No. ofinformative cases.bReferencesforprobes:
See Table I in Ding et al. (1991). These two probes screen the region
flanking the MCC (mutated incolorectal cancer) (Kinzler etal., 1991b)
and APC (familial adenomatous polyposis coli) genes (Kinzler et al.,
1991a; Groden et al., 1991). dThis probe was assigned to the chromo-
some arm where the RB (retinoblastoma) tumour suppressor gene
locates. eThese two probes screen the regions near the locus ofthe p53
tumour suppressor gene.
mative (heterozygosity: 70.5%) and the overall allele loss was
only two out of 55 informative cases (3.6%). The frequency
of allele loss in FLC is significantly lower than that in HCC
(30/186, 16.1%, Ding et al., 1991) [P = 0.03, SE (PI-P2) =
2.7%]. Figure 1 shows the two allelic losses, both of which
occurred in a single patient (No. 3). Only that patient had a
recurrent FLC (Table I). The chromosomal regions deleted in
his tumour were lq42-43 detected by the probe AMS32 and
5p by cMS621. These two probes also showed a high fre-
quency of allele loss in HCC with liver cirrhosis, as
previously reported (Ding et al., 1991).
Patient No. 4 had a synchronous HCC. The HCC of this
patient had an allele loss detected by the probe AMS 43
(12q24.3-qter), but his FLC had no similar allele loss (Figure
2). The probe was informative also in all the other four
patients but showed allele loss in none of them (Table II).
Discussion
This study showed that the frequency of allele loss in fibro-
lamellar carcinoma was very low (2/55, 3.6%). With the same
method, we found a much higher frequency of allele loss in
HCC (30/186, 16.1%) (Ding et al., 1991). For colorectal
carcinomas, patients with a higher frequency of allelic losses
had a considerably worse prognosis than did the other
patients (Vogelstein et al., 1989). A similar correlation was
observed in carcinomas of the pancreas (Ding et al., 1992).
Thus this study showing a much lower frequency of allele
loss in FLC than in HCC is in agreement with the above
observations since FLC has a much better prognosis than
HCC (Craig et at., 1980). Of the five patients with FLC in
this study, the FLC with two allelic losses recurred while the
others did not (Table I).
Previously, we reported that in HCC with liver cirrhosis
the highest frequency of allele loss occurred in chromosomal






Figure 1 Autoradiographs of Southern hybridisations of Patient
No. 3's DNA with AMS32 (1q42-43) and cMS621 (5p). N = non-
tumour tissue DNA; T = tumour tissue DNA. Both show allelic
losses in tumour DNA (indicated by arrows).
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Figure 2 Autoradiograph of Southern hybridisation of Patient
No. 4's DNA with kMS43 (l2q24.3-qter). B = Blood lymphocyte
DNA; N = Non-tumour tissue DNA; H = Hepatocellular carcin-
oma DNA; F = Fibrolammellar variant DNA. Note that the
small allele is deleted in HCC DNA compared with lymphocyte
and non-tumour DNA but, the allele is present in the FLC DNA
(indicated by the arrow).
sis, in 5q35-qter and Flpl3 (Ding et at., 1991). The probes
used for the region l7pl13, i.e. pl44-D6 and pYNZ.22, were
near the locus of the p53 tumour suppressor gene. The high
frequency of allele loss shown by these probes in HCC might
represent the p53 gene loss in the tumour. The specific muta-
tion of codon 249 of the p53 gene has been reported in the
HCC from patients with high exposure to aflatoxin B1 (Hsu
et at., 1991; Bressac et at., 1991). All the HCC cases in our
study were patients from Europe and Egypt, the areas with a
low exposure to aflatoxin B1. No mutation at codon 249 of
the p53 gene has been found (Ding et at., unpublished data).
None of the informative FLC had allele loss in 5q35-qter
and 17pl3 (Table II), the chromosomal regions where our
HCC series showed a high frequency of allele loss. It is of
interest to note that the two allelic losses in the FLC occur-
red in lq42-43 and 5p. A larger study is needed to determine
whether the loss is characteristic of this type of tumour or
due to chance (Lasko et at., 1991). In Patient No. 4 who had
a synchronous HCC and FLC, the HCC showed allelic loss
in the region 12q24.3-qter, but not the FLC.
These results may for the first time show the differences in
genetic background in these two primary liver cancers, in
addition to their clinico-pathological differences.
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